From pathogenesis to clinical practice: Emerging medical treatments for endometriosis

Clemenza S, Sara Clemenza, Flavia Sorbi, Sorbi F, Ivo Noci, Noci I, Tommaso Capezzuoli, Capezzuoli T, Turrini I, Irene Turrini, Carriero C, Carlo Carriero, Buffi N, Nicolò Maria Buffi, Nicolò Buffi, Massimiliano Fambrini, Felice Petraglia
Best practice & research. Clinical obstetrics & gynaecology · 2018 · vol. 51 , pp. 92–101 · doi:10.1016/j.bpobgyn.2018.01.021 · PMID:29559388 · W2794156113
review OA: closed CC0 ⤵ 54 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This review discusses current and emerging medical treatments for endometriosis, covering pathogenesis and their translation into clinical practice.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis is a chronic disease, and a lifelong management plan should be developed by using pharmacological treatment and surgical procedures. The pathogenesis of endometriosis is complicated and has not been definitively established. The mechanisms involved are numerous, and their understanding is constantly evolving. Currently, the first-line drugs act by blocking ovarian function, creating an hypoestrogenic environment. The blockade of estrogen secretion and receptor activity and the activation of progesteron receptors are the main target of several current drugs, as well as those under development. The oral GnRH antogonists, the aromatase inhibitors, SERMs, and SPRMs are the hormonal drugs currently studied for treating endometriosis. The increasing knowledge of the pathogenesis has allowed the development of new treatments. The most studied are the anti-inflammatory drugs, starting from the new NSAIDs to the monoclonal antibodies and the statins. Among the antiangiogenic compounds, a role is suggested for Icon, PPARs, and HDACIs. A new class of drugs is the cannabinoids. The aim of this review was to investigate the new therapeutic hormonal and non-hormonal alternatives to standard treatments.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Antibodies, Monoclonal Antibodies, Monoclonal Antibodies, Monoclonal Anti-Inflammatory Agents Anti-Inflammatory Agents Anti-Inflammatory Agents Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Cannabinoids Cannabinoids Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Randomized Controlled Trials as Topic Receptors, Progesterone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (87)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:55.107525+00:00
License: CC0 · commercial use OK